Most dos­es of No­vo Nordisk's Ozem­pic are re­moved from FDA drug short­age list af­ter sup­ply is­sues

No­vo Nordisk’s type 2 di­a­betes treat­ment Ozem­pic, which is al­so used off-la­bel for weight loss, is back in stock fol­low­ing a months-long short­age, ac­cord­ing to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER